Beneficial Outcome of Urethane Treatment Following Status Epilepticus in a Rat Organophosphorus Toxicity Model
Affiliations
The efficacy of benzodiazepines to terminate electrographic status epilepticus (SE) declines the longer a patient is in SE. Therefore, alternative methods for ensuring complete block of SE and refractory SE are necessary. We compared the ability of diazepam and a subanesthetic dose of urethane to terminate prolonged SE and mitigate subsequent pathologies. Adult Sprague Dawley rats were injected with diisopropylfluorophosphate (DFP) to induce SE. Rats were administered diazepam (10 mg/kg, ip) or urethane (0.8 g/kg, s.c.) 1 h after DFP-induced SE and compared to rats that experienced uninterrupted SE. Large-amplitude and high-frequency spikes induced by DFP administration were quenched for at least 46 h in rats administered urethane 1 h after SE onset as demonstrated by cortical electroencephalography (EEG). By contrast, diazepam interrupted SE but seizures with high power in the 20- to 70-Hz band returned 6-10 h later. Urethane was more effective than diazepam at reducing hippocampal neurodegeneration, brain inflammation, gliosis and weight loss as measured on day 4 after SE. Furthermore, rats administered urethane displayed a 73% reduction in the incidence of spontaneous recurrent seizures after four to eight weeks and a 90% reduction in frequency of seizures in epileptic rats. By contrast, behavioral changes in the light/dark box, open field and a novel object recognition task were not improved by urethane. These findings indicate that in typical rodent SE models, it is the return of SE overnight, and not the initially intense 1-2 h of SE experience, that is largely responsible for neurodegeneration, accompanying inflammation, and the subsequent development of epilepsy.
Moghe M, Kim S, Guan M, Rait A, Pirollo K, Harford J Int J Mol Sci. 2024; 25(14).
PMID: 39062781 PMC: 11276659. DOI: 10.3390/ijms25147539.
Gage M, Vinithakumari A, Mooyottu S, Thippeswamy T Front Microbiomes. 2023; 1.
PMID: 37304619 PMC: 10256240. DOI: 10.3389/frmbi.2022.1006078.
Figueiredo T, Aroniadou-Anderjaska V, Apland J, Rossetti K, Braga M Exp Biol Med (Maywood). 2023; 248(7):612-623.
PMID: 37300407 PMC: 10350803. DOI: 10.1177/15353702231171911.
Insight into Drug Resistance in Status Epilepticus: Evidence from Animal Models.
Wang F, Zhang Q, Wang Y, Chen J, Wang Y Int J Mol Sci. 2023; 24(3).
PMID: 36768361 PMC: 9917109. DOI: 10.3390/ijms24032039.
Cruz-Hernandez A, Roney A, Goswami D, Tewari-Singh N, Brown J Inhal Toxicol. 2022; 34(13-14):412-432.
PMID: 36394251 PMC: 9832991. DOI: 10.1080/08958378.2022.2147257.